“The microbiome is a highly complex and diverse community of microorganisms living in and on the human body,” describes Dr. Kate Markey, Assistant Professor in the Translational Science and ...

A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.

Groundbreaking research in The Journal of Molecular Diagnostics shows that analysis of specific patterns of cell-free DNA ...

Small cell lung cancer (SCLC) remains a challenging cancer type to treat effectively. While patients initially respond to chemotherapy and immunotherapies, the disease almost always returns, often ...

Donor-derived cell-free DNA can aid detection, diagnosis, and monitoring of antibody-mediated rejection after kidney transplantation. Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive biomarker ...

Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial Our findings revealed a ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

When cells expire, they leave behind an activity log of sorts: RNA expelled into blood plasma that reveals changes in gene expression, cellular signaling, tissue injury and other biological processes.

What information could patients and providers learn from DNA found in a blood sample? An expert sat down with CURE to discuss ctDNA misconceptions. For patients with cancer, circulating tumor DNA ...